Siev Michael, Renson Audrey, Tan Hung-Jui, Rose Tracy L, Kang Stella K, Huang William C, Bjurlin Marc A
Department of Urology, Division of Urologic Oncology, NYU Langone Health, New York, NY, USA.
Department of Clinical Research, NYU Langone Hospital - Brooklyn, Brooklyn, NY, USA.
Kidney Cancer. 2020;4(1):49-58. doi: 10.3233/kca-190072. Epub 2020 Mar 30.
To evaluate overall survival (OS) of T1a kidney cancers stratified by histologic subtype and curative treatment including partial nephrectomy (PN), percutaneous ablation (PA), and radical nephrectomy (RN).
We queried the National Cancer Data Base (2004-2015) for patients with T1a kidney cancers who were treated surgically. OS was estimated by Kaplan-Meier curves based on histologic subtype and management. Cox proportional regression models were used to determine whether histologic subtypes and management procedure predicted OS.
46,014 T1a kidney cancers met inclusion criteria. Kaplan Meier curves demonstrated differences in OS by treatment for clear cell, papillary, chromophobe, and cystic histologic subtypes (all < 0.001), but no differences for sarcomatoid ( = 0.110) or collecting duct ( = 0.392) were observed. Adjusted Cox regression showed worse OS for PA than PN among patients with clear cell (HR 1.58, 95%CI [1.44-1.73], papillary RCC (1.53 [1.34-1.75]), and chromophobe RCC (2.19 [1.64-2.91]). OS was worse for RN than PN for clear cell (HR 1.38 [1.28-1.50]) papillary (1.34 [1.16-1.56]) and chromophobe RCC (1.92 [1.43-2.58]). Predictive models using Cox proportional hazards incorporating histology and surgical procedure alone were limited (c-index 0.63) while adding demographics demonstrated fair predictive power for OS (c-index 0.73).
In patients with pathologic T1a RCC, patterns of OS differed by surgery and histologic subtype. Patients receiving PN appears to have better prognosis than both PA and RN. However, the incorporation of histologic subtype and treatment modality into a risk stratification model to predict OS had limited utility compared with variables representing competing risks.
评估按组织学亚型和包括部分肾切除术(PN)、经皮消融术(PA)及根治性肾切除术(RN)在内的根治性治疗分层的T1a期肾癌患者的总生存期(OS)。
我们查询了国家癌症数据库(2004 - 2015年)中接受手术治疗的T1a期肾癌患者。基于组织学亚型和治疗方式,采用Kaplan-Meier曲线评估总生存期。使用Cox比例回归模型确定组织学亚型和治疗程序是否可预测总生存期。
46,014例T1a期肾癌符合纳入标准。Kaplan-Meier曲线显示,透明细胞、乳头状、嫌色细胞和囊性组织学亚型的治疗总生存期存在差异(均<0.001),但未观察到肉瘤样(=0.110)或集合管(=0.392)组织学亚型存在差异。校正后的Cox回归显示,透明细胞癌(风险比[HR]1.58,95%置信区间[CI][1.44 - 1.73])、乳头状肾细胞癌(1.53[1.34 - 1.75])和嫌色细胞肾细胞癌(2.19[1.64 - 2.91])患者中,接受PA治疗的总生存期比PN差。透明细胞癌(HR 1.38[1.28 - 1.50])、乳头状癌(1.34[1.16 - 1.56])和嫌色细胞肾细胞癌(1.92[1.43 - 2.58])患者中,接受RN治疗的总生存期比PN差。仅纳入组织学和手术程序的Cox比例风险预测模型效果有限(c指数0.63),而加入人口统计学因素后对总生存期显示出较好的预测能力(c指数0.73)。
在病理T1a期肾细胞癌患者中,总生存期模式因手术和组织学亚型而异。接受PN治疗的患者预后似乎比PA和RN都要好。然而,与代表竞争风险的变量相比,将组织学亚型和治疗方式纳入风险分层模型以预测总生存期的效用有限。